The FDA previously approved Dupixent in May 2022 to treat eosinophilic esophagitis in patients aged 12 years and older.
FDA Approves Expanded Indication for Dupixent to Treat Eosinophilic Esophagitis in Pediatric Patients
The FDA previously approved Dupixent in May 2022 to treat eosinophilic esophagitis in patients aged 12 years and older.